News Highlights $テスラ(TSLA.US)$shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
Insiders selling Boston Scientific shares, even below current price, is discouraging. Yet, high insider ownership could imply company's interest in all shareholders.
Boston Scientific's high P/E ratio is attributed to investors' optimism about its strong future growth and market outperformance. Shareholders' confidence in the company's future earnings supports the current P/E ratio and share price.
Boston Scientific's EPS growth and insider ownership hint at future success, but investors should note the 2 warning signs. Its strong performance makes it a company to watch.
Piper Sandler analysts find Boston Scientific, Expedia Group, Progressive Corporation, Skechers U.S.A., Synovus Financial, and Zoetis Inc. stocks attractive due to their individual strengths and positive trends.
Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.
Morning Movers Gapping up $Fisker(FSR.US)$Shares of the electric vehicle company popped 9.3% after Fisker said that it grew deliveries by over 300% between the third and fourth quarter, helped by strong demand for the company’s Ocean SUV. Fisker said it intends to announce a plan in January to continue accelerating sales and deliveries. $エヌビディア(NVDA.US)$Nvidia shares ticked 0.3% higher after the chipmaker announced the launc...
Baird analysts anticipate Insulet's earnings to grow faster than their annual sales of approx. 20%. DexCom's margins predicted to expand with sales growth over 20% annually before GLP-1s impact. Boston Scientific considered a top-level medtech enterprise by Baird's Rescott.
Insiders selling Boston Scientific shares, even below current price, flags unsettling sentiment over company valuation. Absence of insider buying in last year doesn't instill confidence, insider buying would bolster it.
104575863 : hai
103625245 : hai guys
74049856 : someone please close my account